Aktiesnakken — Oktober 2009
-
karbold... 8,75------ 24,60
-
se lige GEN - det må være det første biotekselskab, der ingen effekt ser af en FDA approval. Hvad sker der!?
-
nu bomber kreditfissen GEN igen. Hvordan pokker kan det lade sig gøre at slutte en uge lavere end den begyndte med en FDA approval?
-
men det kunne dog have været værre. check lige behandlingen som NEUR har fået det sidste par uger...
-
Der kommer vistnok yderligere data fra den mislykkede NHL refrac, som kan kaste noget lys over effekten. Arzerra outperformede staid
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind